Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease
- PMID: 21991518
- PMCID: PMC3168494
- DOI: 10.5402/2011/592404
Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease
Abstract
Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of clinicopathologic conditions ranging from steatosis alone to nonalcoholic steatohepatitis (NASH), with varying risks for progression to cirrhosis and hepatocellular carcinoma. There is mounting evidence that NAFLD not only complicates obesity, but also perpetuates its metabolic consequences. Critical event that leads to progressive liver injury in NAFLD is unknown. Obesity reflects a generalized proinflammatory state with its increased inflammatory markers like C reactive protein, IL-6, IL-8, IL-10, PAI-1, TNF-α, and hepatocyte growth factor. The elevated production of these adipokines is increasingly considered to be important in the development of diseases linked to obesity and the metabolic syndrome. Disordered cytokine production is likely to play a role in the pathogenesis of NAFLD. There is no effective treatment for NAFLD, though weight loss may halt disease progression and revert histological changes, the underlying mechanism remaining elusive. All stages of the disease pathway from prevention, early identification/diagnosis, and treatment require an understanding of the pathogenesis of liver injury in NAFLD.
Similar articles
-
Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.Am J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G462-G472. doi: 10.1152/ajpgi.00358.2018. Epub 2019 Jan 17. Am J Physiol Gastrointest Liver Physiol. 2019. PMID: 30653341
-
The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Am J Physiol Gastrointest Liver Physiol. 2020 Sep 1;319(3):G345-G360. doi: 10.1152/ajpgi.00055.2020. Epub 2020 Aug 5. Am J Physiol Gastrointest Liver Physiol. 2020. PMID: 32755310 Free PMC article.
-
Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.Int J Mol Sci. 2021 Apr 26;22(9):4495. doi: 10.3390/ijms22094495. Int J Mol Sci. 2021. PMID: 33925827 Free PMC article. Review.
-
Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma.J Cell Biochem. 2022 Oct;123(10):1553-1584. doi: 10.1002/jcb.30252. Epub 2022 Jul 12. J Cell Biochem. 2022. PMID: 35818831 Review.
-
Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.JHEP Rep. 2020 Oct 9;3(1):100193. doi: 10.1016/j.jhepr.2020.100193. eCollection 2021 Feb. JHEP Rep. 2020. PMID: 33294831 Free PMC article.
Cited by
-
Effect of Intermittent vs. Continuous Energy Restriction on Visceral Fat: Protocol for The Healthy Diet and Lifestyle Study 2 (HDLS2).Nutrients. 2024 May 14;16(10):1478. doi: 10.3390/nu16101478. Nutrients. 2024. PMID: 38794715 Free PMC article.
-
Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of metabolic dysfunction-associated steatotic liver disease in a Chinese population.Lipids Health Dis. 2024 Apr 14;23(1):104. doi: 10.1186/s12944-024-02100-5. Lipids Health Dis. 2024. PMID: 38616253 Free PMC article.
-
Visceral and subcutaneous abdominal fat is associated with non-alcoholic fatty liver disease while augmenting Metabolic Syndrome's effect on non-alcoholic fatty liver disease: A cross-sectional study of NHANES 2017-2018.PLoS One. 2024 Feb 23;19(2):e0298662. doi: 10.1371/journal.pone.0298662. eCollection 2024. PLoS One. 2024. PMID: 38394065 Free PMC article.
-
LASSO-derived model for the prediction of lean-non-alcoholic fatty liver disease in examinees attending a routine health check-up.Ann Med. 2024 Dec;56(1):2317348. doi: 10.1080/07853890.2024.2317348. Epub 2024 Feb 16. Ann Med. 2024. PMID: 38364216 Free PMC article.
-
Current Perspectives: Obesity and Neurodegeneration - Links and Risks.Degener Neurol Neuromuscul Dis. 2023 Dec 31;13:111-129. doi: 10.2147/DNND.S388579. eCollection 2023. Degener Neurol Neuromuscul Dis. 2023. PMID: 38196559 Free PMC article. Review.
References
-
- Seidell JC. Epidemiology of obesity. Seminars in Vascular Medicine. 2005;5(1):3–14. - PubMed
-
- The World Health Organization. WHO Technical Report Series 894. Geneva, Switzerland: 2000. Preventing and managing the global epidemic. - PubMed
-
- Kral JG, Schaffner F, Pierson RN, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism. 1993;42(5):548–551. - PubMed
-
- Ramsey-Stuart G. Hepatic steatosis and morbid obesity. Obesity Surgery. 1993;3(2):157–159. - PubMed
-
- van Steenbergen W, Lanckmans S. Liver disturbances in obesity and diabetes mellitus. International Journal of Obesity. 1995;19(supplement 1):S27–S36. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous